| Name | Oakmont Manor |
|---|---|
| Location | 1100 Grandview Drive, Flatwoods, Kentucky |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 85 |
| Occupancy Rate | 88.12% |
| Medicare ID (CCN) | 185250 |
| Legal Business Name | Oakmont Operations Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1730631367 |
| Organization Name | OAKMONT OPERATIONS, LLC |
| Address | 1100 Grandview Dr, Flatwoods, KY 41139 |
| Phone Number | 859-626-8106 |
News Archive
MicroBiome Therapeutics LLC, a biotechnology company developing pharmaceutical and medical food products that shift the human microbiome in specific ways for improved health, today reported publication of a case report suggesting a potentially important new application for its lead product, NM504. NM504 is in clinical development to promote healthy blood glucose levels and metabolic fitness in prediabetic and diabetic populations.
Adults who involuntarily lose solid or liquid stools no longer have to suffer in silence, thanks to new national standards on treating and managing the condition, known as faecal incontinence.
Schizophrenia may blur the boundary between internal and external realities by overactivating a brain system that is involved in self-reflection, and thus causing an exaggerated focus on self, a new MIT and Harvard brain imaging study has found.
Hemodialysis patients with and without diabetes are at risk for foot ulceration, say UK researchers who believe preventive resources must be directed toward both patient groups.
Cara Therapeutics, Inc. today announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa opioid agonist, CR845. The 46 patient Phase II, multi-center, double-blind, placebo-controlled study was conducted at eight hospitals in the United States and evaluated the efficacy and safety of CR845 in women following laparoscopic-assisted hysterectomy.
› Verified 5 days ago
| NPI Number | 1851380455 |
| Organization Name | OAKMONT LLC |
| Doing Business As | OAKMONT MANOR |
| Address | 1100 Grandview Dr, Flatwoods, KY 41139 |
| Phone Number | 606-836-3187 |
News Archive
MicroBiome Therapeutics LLC, a biotechnology company developing pharmaceutical and medical food products that shift the human microbiome in specific ways for improved health, today reported publication of a case report suggesting a potentially important new application for its lead product, NM504. NM504 is in clinical development to promote healthy blood glucose levels and metabolic fitness in prediabetic and diabetic populations.
Adults who involuntarily lose solid or liquid stools no longer have to suffer in silence, thanks to new national standards on treating and managing the condition, known as faecal incontinence.
Schizophrenia may blur the boundary between internal and external realities by overactivating a brain system that is involved in self-reflection, and thus causing an exaggerated focus on self, a new MIT and Harvard brain imaging study has found.
Hemodialysis patients with and without diabetes are at risk for foot ulceration, say UK researchers who believe preventive resources must be directed toward both patient groups.
Cara Therapeutics, Inc. today announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa opioid agonist, CR845. The 46 patient Phase II, multi-center, double-blind, placebo-controlled study was conducted at eight hospitals in the United States and evaluated the efficacy and safety of CR845 in women following laparoscopic-assisted hysterectomy.
› Verified 5 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
MicroBiome Therapeutics LLC, a biotechnology company developing pharmaceutical and medical food products that shift the human microbiome in specific ways for improved health, today reported publication of a case report suggesting a potentially important new application for its lead product, NM504. NM504 is in clinical development to promote healthy blood glucose levels and metabolic fitness in prediabetic and diabetic populations.
Adults who involuntarily lose solid or liquid stools no longer have to suffer in silence, thanks to new national standards on treating and managing the condition, known as faecal incontinence.
Schizophrenia may blur the boundary between internal and external realities by overactivating a brain system that is involved in self-reflection, and thus causing an exaggerated focus on self, a new MIT and Harvard brain imaging study has found.
Hemodialysis patients with and without diabetes are at risk for foot ulceration, say UK researchers who believe preventive resources must be directed toward both patient groups.
Cara Therapeutics, Inc. today announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa opioid agonist, CR845. The 46 patient Phase II, multi-center, double-blind, placebo-controlled study was conducted at eight hospitals in the United States and evaluated the efficacy and safety of CR845 in women following laparoscopic-assisted hysterectomy.
› Verified 5 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 2 |
| Total Amount of Fines in Dollars | $1625 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 2 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 7.46 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 5.64 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 39.08 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.55 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 5.69 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 5.98 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.45 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 7.63 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 96.85 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0.7 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 18.5 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 39.74 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 8.33 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 89.94 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 98.76 | 82.93 |
News Archive
MicroBiome Therapeutics LLC, a biotechnology company developing pharmaceutical and medical food products that shift the human microbiome in specific ways for improved health, today reported publication of a case report suggesting a potentially important new application for its lead product, NM504. NM504 is in clinical development to promote healthy blood glucose levels and metabolic fitness in prediabetic and diabetic populations.
Adults who involuntarily lose solid or liquid stools no longer have to suffer in silence, thanks to new national standards on treating and managing the condition, known as faecal incontinence.
Schizophrenia may blur the boundary between internal and external realities by overactivating a brain system that is involved in self-reflection, and thus causing an exaggerated focus on self, a new MIT and Harvard brain imaging study has found.
Hemodialysis patients with and without diabetes are at risk for foot ulceration, say UK researchers who believe preventive resources must be directed toward both patient groups.
Cara Therapeutics, Inc. today announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa opioid agonist, CR845. The 46 patient Phase II, multi-center, double-blind, placebo-controlled study was conducted at eight hospitals in the United States and evaluated the efficacy and safety of CR845 in women following laparoscopic-assisted hysterectomy.
› Verified 5 days ago